Strategic consulting and PK/PD modelling services dedicated to preclinical and clinical biotherapeutics development



We support the translation of innovation into pharmacological concepts and therapies. We believe that the most innovative therapeutic ideas deserve the best development tools. We use Systems Pharmacology as a key tool to maximize the success of your preclinical program, clinical study or registration.


Our services includes consultancy and implementation of systems pharmacology and PK/PD modelling for target assessment, format selection, compound design, candidate selection, design and analysis of preclinical PK/PD and GLP toxicology studies, first in human dose selection, paediatric dose selection  and dose / regimen finding studies.

Why choose us

Our methods have been successfully applied in global pharmaceutical companies with tangible results including patents. We have the unique tested expertise developing bi-specifics, antibody-drug conjugates, scFv’s, nanobodies, cell based therapies to provide tailored support for your program.


label_web_iBxN_withBGLYO-X is member of the iBx Network. We provide integrated consulting in toxicology, pathology, preclinical and clinical pharmacology and regulatory strategies.

lixoft_labelLYO-X is partnering with Lixoft to provide you access to Monolix the scientifically and technologically most advanced software for preclinical and clinical data analysis.


Learn more why Systems Pharmacology is a critical tool for the development of novel Biologics

  • 12th Basel M&S Seminar: ‘Modelling … AND SIMULATION’

    We will present at the 12th Basel M&S Seminar Sept 20, 2016 on ‘Modelling … AND SIMULATION’. Yes, although its is called M&S the reality is quite different with a historically large emphasis on modelling. We will discuss the relevance of simulations and their key importance and provide a showcase … Read More

  • ASCO 2016 abstract 2

    Population pharmacokinetics of CAP7.1 and the effect on total target lesion size in adult patients with biliary tract cancer. Matthias Machacek, Ulrich-Frank Pape, Ulrich Keilholz, Marianne Sinn, Stefan Kasper, Johannes Meiler, Arndt Vogel, Lothar Mueller, Karel Caca, Jan Kuhlmann, Oswald Burkhard, Victor Rodriguez Laval, Glyn Steventon, Nalan Utku, Holger Jansen; LYO-X … Read More

  • ASCO 2016 abstract 1

    Population pharmacokinetics of PQR309, a dual PI3K/mTOR inhibitor in adult patients with advanced solid tumors. Matthias Machacek1, Lionel Renaud1, Sasa Dimitrijevic2, Debora Schmitz2, Elena Ivanova2, Karin Jorga3; 1LYO-X GmbH, Allschwil, Switzerland; 2PIQUR Therapeutics AG, Basel, Switzerland; 3Karin Jorga Life Science Consulting GmbH, Basel, Switzerland. J Clin Oncol 34, 2016 (suppl; abstr e14101).